Search

Your search keyword '"MED/38 - PEDIATRIA GENERALE E SPECIALISTICA"' showing total 4 results
Start Over Descriptor "MED/38 - PEDIATRIA GENERALE E SPECIALISTICA" Publisher wolters kluwer health
4 results on '"MED/38 - PEDIATRIA GENERALE E SPECIALISTICA"'

1. Hypersensitivity Reactions to Native E. coli L-asparaginase in Children with Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction

Author

Moricke, A, Rizzari, C, Alten, J, Attarbaschi, A, Beier, R, Biondi, A, Burkhardt, B, Bodmer, N, Boos, J, Cario, G, Conter, V, Flotho, C, Kulozik, A, Lanvers-Kaminsky, C, Mann, G, Niggli, F, Silvestri, D, Von Stackelberg, A, Stanulla, M, Valsecchi, M, Schrappe, M, Zimmermann, M, Moricke A., Rizzari C., Alten J., Attarbaschi A., Beier R., Biondi A., Burkhardt B., Bodmer N., Boos J., Cario G., Conter V., Flotho C., Kulozik A., Lanvers-Kaminsky C., Mann G., Niggli F., Silvestri D., Von Stackelberg A., Stanulla M., Valsecchi MG., Schrappe M., Zimmermann M., Moricke, A, Rizzari, C, Alten, J, Attarbaschi, A, Beier, R, Biondi, A, Burkhardt, B, Bodmer, N, Boos, J, Cario, G, Conter, V, Flotho, C, Kulozik, A, Lanvers-Kaminsky, C, Mann, G, Niggli, F, Silvestri, D, Von Stackelberg, A, Stanulla, M, Valsecchi, M, Schrappe, M, Zimmermann, M, Moricke A., Rizzari C., Alten J., Attarbaschi A., Beier R., Biondi A., Burkhardt B., Bodmer N., Boos J., Cario G., Conter V., Flotho C., Kulozik A., Lanvers-Kaminsky C., Mann G., Niggli F., Silvestri D., Von Stackelberg A., Stanulla M., Valsecchi MG., Schrappe M., and Zimmermann M.

Published
2023

2. Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children with Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol

Author

Rizzari, C, Möricke, A, Valsecchi, M, Conter, V, Zimmermann, M, Silvestri, D, Attarbaschi, A, Niggli, F, Barbaric, D, Stary, J, Elitzur, S, Cario, G, Vinti, L, Boos, J, Zucchetti, M, Lanvers-Kaminsky, C, Von Stackelberg, A, Biondi, A, Schrappe, M, Rizzari C., Möricke A., Valsecchi M. G., Conter V., Zimmermann M., Silvestri D., Attarbaschi A., Niggli F., Barbaric D., Stary J., Elitzur S., Cario G., Vinti L., Boos J., Zucchetti M., Lanvers-Kaminsky C., Von Stackelberg A., Biondi A., Schrappe M., Rizzari, C, Möricke, A, Valsecchi, M, Conter, V, Zimmermann, M, Silvestri, D, Attarbaschi, A, Niggli, F, Barbaric, D, Stary, J, Elitzur, S, Cario, G, Vinti, L, Boos, J, Zucchetti, M, Lanvers-Kaminsky, C, Von Stackelberg, A, Biondi, A, Schrappe, M, Rizzari C., Möricke A., Valsecchi M. G., Conter V., Zimmermann M., Silvestri D., Attarbaschi A., Niggli F., Barbaric D., Stary J., Elitzur S., Cario G., Vinti L., Boos J., Zucchetti M., Lanvers-Kaminsky C., Von Stackelberg A., Biondi A., and Schrappe M.

Abstract

The incidence of hypersensitivity reactions (HSRs) to PEG-asparaginase (PEG-ASNase) was evaluated in 6136 children with ALL enrolled in the AIEOP-BFM ALL 2009 study. Patients with B-cell precursor-acute lymphoblastic leukemia (BCP-ALL) were stratified as standard-risk/medium-risk (MR)/high-risk (HR) and those with T-ALL as non-High/HR. PEG-ASNase was administered intravenously at 2500 IU/sqm/dose. All patients received 2 PEG-ASNase doses in induction; thereafter non-HR versus HR patients received 1 versus 6 PEG-ASNase doses, respectively. After the single regular dose of PEG-ASNase at the beginning of delayed intensification, BCP-ALL-MR patients were randomized to receive 9 additional PEG-ASNase doses every 2 weeks (experimental arm [EA]) versus none (standard arm [SA]); HR patients were randomized to receive, in consolidation, 4 weekly PEG-ASNase doses (EA) versus none (SA). The HSR cumulative incidence (CI) was estimated adjusting for competing risks. An HSR occurred in 472 of 6136 (7.7%) patients. T-non- HR/BCP-Standard-Risk, BCP-MR-SA, BCP-MR-EA, HR-SA and HR-EA patients had 1-year-CI-HSR (±SE) rates of 5.2% (0.5), 5.2% (0.5), 4.0% (0.8), 20.2% (1.2), and 6.4% (1.3), respectively. The randomized intensification of PEG-ASNase did not significantly impact on HSR incidence in BCP-MR patients (1-y-CI-HSR 3.8% [0.8] versus 3.2% [0.6] in MR-EA versus MR-SA; P = 0.55), while impacted significantly in HR patients (1-y-CI-HSR 6.4% [1.3] versus 17.9% [1.8] in HR-EA and HR-SA, respectively; P < 0.001). The CI-HSR was comparable among non-HR groups and was not increased by a substantial intensification of PEG-ASNase in the BCP-MR-EA group whilst it was markedly higher in HR-SA than in HR-EA patients, suggesting that, in such a chemotherapy context, a continuous exposure to PEG-ASNase reduces the risk of developing an HSR.

Published
2023

3. Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children with Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol

Author

Rizzari C., Möricke A., Valsecchi M. G., Conter V., Zimmermann M., Silvestri D., Attarbaschi A., Niggli F., Barbaric D., Stary J., Elitzur S., Cario G., Vinti L., Boos J., Zucchetti M., Lanvers-Kaminsky C., Von Stackelberg A., Biondi A., Schrappe M., Rizzari, C, Möricke, A, Valsecchi, M, Conter, V, Zimmermann, M, Silvestri, D, Attarbaschi, A, Niggli, F, Barbaric, D, Stary, J, Elitzur, S, Cario, G, Vinti, L, Boos, J, Zucchetti, M, Lanvers-Kaminsky, C, Von Stackelberg, A, Biondi, A, and Schrappe, M

Subjects
MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, acute lymphoblastic leukemia, childhood, chemoterapy, asparaginase
Abstract

The incidence of hypersensitivity reactions (HSRs) to PEG-asparaginase (PEG-ASNase) was evaluated in 6136 children with ALL enrolled in the AIEOP-BFM ALL 2009 study. Patients with B-cell precursor-acute lymphoblastic leukemia (BCP-ALL) were stratified as standard-risk/medium-risk (MR)/high-risk (HR) and those with T-ALL as non-High/HR. PEG-ASNase was administered intravenously at 2500 IU/sqm/dose. All patients received 2 PEG-ASNase doses in induction; thereafter non-HR versus HR patients received 1 versus 6 PEG-ASNase doses, respectively. After the single regular dose of PEG-ASNase at the beginning of delayed intensification, BCP-ALL-MR patients were randomized to receive 9 additional PEG-ASNase doses every 2 weeks (experimental arm [EA]) versus none (standard arm [SA]); HR patients were randomized to receive, in consolidation, 4 weekly PEG-ASNase doses (EA) versus none (SA). The HSR cumulative incidence (CI) was estimated adjusting for competing risks. An HSR occurred in 472 of 6136 (7.7%) patients. T-non- HR/BCP-Standard-Risk, BCP-MR-SA, BCP-MR-EA, HR-SA and HR-EA patients had 1-year-CI-HSR (±SE) rates of 5.2% (0.5), 5.2% (0.5), 4.0% (0.8), 20.2% (1.2), and 6.4% (1.3), respectively. The randomized intensification of PEG-ASNase did not significantly impact on HSR incidence in BCP-MR patients (1-y-CI-HSR 3.8% [0.8] versus 3.2% [0.6] in MR-EA versus MR-SA; P = 0.55), while impacted significantly in HR patients (1-y-CI-HSR 6.4% [1.3] versus 17.9% [1.8] in HR-EA and HR-SA, respectively; P < 0.001). The CI-HSR was comparable among non-HR groups and was not increased by a substantial intensification of PEG-ASNase in the BCP-MR-EA group whilst it was markedly higher in HR-SA than in HR-EA patients, suggesting that, in such a chemotherapy context, a continuous exposure to PEG-ASNase reduces the risk of developing an HSR.

Published
2023

4. Hypersensitivity Reactions to Native E. coli L-asparaginase in Children with Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction

Author

Moricke A., Rizzari C., Alten J., Attarbaschi A., Beier R., Biondi A., Burkhardt B., Bodmer N., Boos J., Cario G., Conter V., Flotho C., Kulozik A., Lanvers-Kaminsky C., Mann G., Niggli F., Silvestri D., Von Stackelberg A., Stanulla M., Valsecchi MG., Schrappe M., Zimmermann M., Moricke, A, Rizzari, C, Alten, J, Attarbaschi, A, Beier, R, Biondi, A, Burkhardt, B, Bodmer, N, Boos, J, Cario, G, Conter, V, Flotho, C, Kulozik, A, Lanvers-Kaminsky, C, Mann, G, Niggli, F, Silvestri, D, Von Stackelberg, A, Stanulla, M, Valsecchi, M, Schrappe, M, and Zimmermann, M

Subjects
acute lymphoblastic leukemia, immunotherapy, MED/38 - PEDIATRIA GENERALE E SPECIALISTICA, chemotherapy, childhood
Published
2023

Catalog

Books, media, physical & digital resources
See catalog results